Alector

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Alector sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 6 completed early-phase tilt top decile by trial count

Alector: 10 sponsored US clinical trials, none currently recruiting.

Alector sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 2 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 2 trials.

Top-decile sponsor footprint

Alector ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

6 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (60.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

TERMINATED Phase 3

Continuation Study for Latozinemab

NCT06111014
TERMINATED Phase 2

A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

NCT05744401
TERMINATED Phase 2

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

NCT05053035
COMPLETED Phase 2

A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

NCT04592874
TERMINATED Phase 3

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

NCT04374136
COMPLETED Phase 1

A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101

NCT04111666
COMPLETED Phase 2

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

NCT03987295
COMPLETED Phase 1

First in Human Study for Safety and Tolerability of AL003.

NCT03822208
COMPLETED Phase 1

A Phase I Study for Safety and Tolerability of AL002.

NCT03635047
COMPLETED Phase 1

A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation

NCT03636204

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 4
Phase 3 2

Therapeutic Areas

Healthy 2
Frontotemporal Dementia 1
Alzheimer Disease 1

How the Alector early-phase archive is shaped

10 indexed studies, none listed as recruiting (0% open); 6 completed (60%).

Phase mix: 2 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Healthy (2 trials), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Alector: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Alector sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share AlectorAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Alector sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Alector sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Alector page

10 registered trials is a research-attention snapshot, not an endorsement of Alector or any single study.

  • None of Alector's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Healthy is the condition Alector studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Alector pipeline card: 10 registered trials from official public datasets.Report a data error.